Skip to main content

Table 5 Summary of most common grade 3 and grade 4 toxicities in the four groups (i.e., reported in ≥5% of patients in any group)

From: Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

  Arm A Arm B Arm C Arm D
(N=59) (N=62) (N=58) (N=59)
  G3 G4 G3 G4 G3 G4 G3 G4
Neutropenia 24 (40.7) 22 (37.3) 22 (35.5) 7 (11.3) 15 (25.9) 4 (6.9) 23 (39.0) 11 (18.6)
Leukopenia 15 (25.4) 1 (1.7) 7 (11.3) 3 (4.8) 6 (10.3) 0 (0.0) 6 (10.2) 1 (1.7)
ALT increased 1 (1.7) 0 (0.0) 5 (8.1) 0 (0.0) 8 (13.8) 0 (0.0) 6 (10.2) 0 (0.0)
Diarrhoea 0 (0.0) 2 (3.4) 0 (0.0) 0 (0.0) 4 (6.9) 0 (0.0) 0 (0.0) 0 (0.0)
Myalgia 0 (0.0) 0 (0.0) 4 (6.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Alopecia 4 (6.8) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.7) 0 (0.0) 1 (1.7) 0 (0.0)
Hepatotoxicitya 0 (0.0) 0 (0.0) 1 (1.6) 0 (0.0) 0 (0.0) 0 (0.0) 3 (5.1) 0 (0.0)
Asthenia 4 (6.8) 0 (0.0) 3 (4.8) 0 (0.0) 5 (8.6) 0 (0.0) 6 (10.2) 1 (1.7)
Fatigue 3 (5.1) 0 (0.0) 3 (4.8) 0 (0.0) 3 (5.2) 0 (0.0) 4 (6.8) 0 (0.0)
  1. Data are number (%) of patient; G = CTC Grade.
  2. aALT are included in hepatotoxicities, but were separately reported by different study investigators.
  3. Arm A: docetaxel and gemcitabine with 3-weekly schedule; Arm B: paclitaxel and gemcitabine with 3-weekly schedule; Arm C: docetaxel and gemcitabine with weekly schedule; Arm D: paclitaxel and gemcitabine with weekly schedule.